BioPharma Resources

Drug Trial Radar · NCT07143448

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 19, 2026

Primary completion

Mar 2028

Study completion Nov 2028

Sponsor

Lead sponsor
35Pharma Inc., a GSK companyIndustry
Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • HS235Biological

    Subcutaneous Injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Number of Adverse Events (AEs)Time frame: up to 29 weeks

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigational Site-102

    Tampa, Florida · Recruiting

  • Investigational Site-101

    Boston, Massachusetts · Recruiting

  • Investigational Site-104

    Providence, Rhode Island · Recruiting

  • Investigational Site-305

    Barcelona, Spain · Recruiting

  • Investigational Site- 301

    Barcelona, Spain · Recruiting

  • Investigational Site-308

    Madrid, Spain · Recruiting

  • Investigational Site-903

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.